Park Ha Biological Technology Co., Ltd.
corporate_fare Company Profile
Park Ha Biological Technology Co., Ltd. (NASDAQ:BYAH) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 28 items for BYAH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-11, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for BYAH spans 6-K, 424B5.
Recent high-impact activity:
- Park Ha Biological Closes $2.97M PIPE at $2.75/Share with Warrants
- Park Ha Biological Dismisses WWC, P.C., Appoints HTL International as New Auditor
- Park Ha Biological Sets 1-for-8 Reverse Split Effective August 6 to Regain Nasdaq Compliance
- Park Ha Biological Raises $1.8M in Deeply Discounted Private Placement, Adding to Dilution Concerns
- Park Ha Biological Reports $918K Net Loss, Cash Plummets to $628K; Massive Dilution Authorized
Financial Snapshot
Short Interest & Short Volume
2.15 days to coverFINRA reported short interest of 14,014 shares in BYAH as of the October 30, 2026 settlement, a 52.6% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 34.3% of BYAH volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for BYAH, detected from its recent SEC filings · based on capital-structure filings through 2026-09-11.
Offering Finalized · Significant Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
BYAH files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.